Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab [PDF]
Radiology and OncologyThe current Barcelona Clinic Liver Cancer (BCLC) classification recommends systemic treatment with atezolizumab and bevacizumab as the first-line therapy for advanced hepatocellular carcinoma (HCC).
Popovic Peter +5 more
doaj +2 more sources
Real-life experience in the treatment of gallbladder carcinoma by transarterial radioembolization: a multicenter retrospective study [PDF]
EJNMMI ReportsPurpose Patients with liver metastases from gallbladder carcinoma have limited treatment options. This retrospective multicenter study evaluated overall survival, tumor control and safety after transarterial radioembolization in this rare patient group ...
Thomas Dertnig +9 more
doaj +2 more sources
Efficacy and Safety of Transarterial Radioembolization in Elderly Patients with Hepatocellular Carcinoma: A Single-Center Experience [PDF]
The Turkish Journal of GastroenterologyBackground/Aims: Hepatocellular carcinoma is a major cause of mortality and morbidity in both cirrhotic and non-cirrhotic patients, and most patients are suitable for locoregional and/or systemic therapy at the time of diagnosis.
Ümit Karaoğullarından +9 more
doaj +2 more sources
Transarterial Radioembolization for Hepatocellular Carcinoma in Korea: Current Clinical Practices, Facility Requirements, and Patient Selection [PDF]
Journal of the Korean Society of RadiologyBefore initiating Yttrium-90 (90Y) radioembolization, both the interventional radiology and nuclear medicine departments must prepare facilities for radionuclide handling, implement appropriate radiation protection and monitoring measures, and ensure ...
Dongho Hyun
doaj +2 more sources
Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes
Cancer MedicineBackground Post‐embolization syndrome after transarterial chemoembolization (TACE) and Yttrium‐90 radioembolization (TARE) causes significant morbidity.
Hanzhou Li +10 more
doaj +2 more sources
Radioembolization for hepatocellular carcinoma: what clinicians need to know [PDF]
Journal of Liver Cancer, 2022 Transarterial radioembolization (TARE) with yttrium 90 (90Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea.
Jin Woo Choi, Hyo-Cheol Kim
doaj +1 more source
Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis [PDF]
Frontiers in OncologyXiangzhong Huang +2 more
exaly +2 more sources
Liver Research, 2021 Patients with recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) have a poor prognosis owing to rapid tumor progression.
Jian-Wen Zhang +6 more
doaj +1 more source
Contrast-enhanced Ultrasound Assessment of Treatment Response in a Patient with Multifocal Hepatocellular Carcinoma Treated with Transarterial Chemo and Radioembolization [PDF]
Advanced Ultrasound in Diagnosis and Therapy, 2021 Minimally invasive locoregional therapies have become important treatment options for patients with intermediate or late-stage hepatocellular carcinoma (HCC) who are ineligible for surgical resection or liver transplantation.
Esika Savsani, Mohamed Tantawi, MD, Corinne E. Wessner, MBA, RDMS, RVT, Philip Lee, MD, Andrej Lyshchik, MD, PhD, Kevin Anton, MD, PhD, Colette M. Shaw, MD, Ji-Bin Liu, MD, John R. Eisenbrey, PhD
doaj +1 more source
PLoS ONE, 2021 BackgroundRecently, the use of Yttrium-90 transarterial radioembolization in non-surgical hepatocellular carcinoma was suggested but the evidence supporting its use is unclear.MethodsWe searched Medline, Embase, Web of Science and Cochrane CENTRAL from ...
Simon Lemieux +6 more
doaj +1 more source